Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1977 Jan;59(1):147–156. doi: 10.1111/j.1476-5381.1977.tb06989.x

The effects of glucagon, secretin, pancreozymin and pentagastrin on the hepatic arterial vascular bed of the dog.

P D Richardson, P G Withrington
PMCID: PMC1667720  PMID: 836995

Abstract

1 The sympathetically-innervated arterial vascular bed of the dog's liver was perfused from a femoral artery. Arterial blood flow and perfusion pressure were monitored continuously and the hepatic arterial vascular resistance (HAVR) calculated from these measurements. 2 Commercial preparations of secretin, pancroezymin, glucagon and pentagastrin were administered by intra-arterial (i.a.) injection and infusion. 3 Secretin and pancreozymin by injection caused dose-dependent hepatic arterial vasodilatation, and on a molar basis were both more potent than glucagon or pentagastrin. 4 Intra-arterial infusions of secretin and pancreozymin caused hepatic arterial vasodilatation at calculated blood concentrations close to those measured under physiological conditions by other investigators. The vasodilatation was of the same duration as that of the hormone infusions. 5 Pentagastrin by i.a. injection caused dose-dependent hepatic arterial vasodilatation; by i.a. infusion, vasodilatation occurred but there was marked 'escape' from the effects during the continued infusion. 6 As reported previously, glucagon by injection caused dose-dependent hepatic arterial vasodilatation of long duration; by infusion, glucagon caused vasodilatation that persisted after the cessation of the infusion. 7 Glucagon infused i.a. inhibited the vasoconstricter effects of i.a. noradrenaline, over the same range of infusions that caused hepatic arterial vasodilatation. 8 Secretin or pancreozymin did not antagonize the effects of noradrenaline on the hepatic arterial vascular bed at any doses used. 9 Pentagastrin did not antagonize the vasoconstrictor effect of noradrenaline whether hepatic arterial vasodilatation resulted from the pentagastrin infusion, or not. 10 These results are discussed with respect to the possible control of the hepatic arterial vascular bed by gastrointestinal hormones.

Full text

PDF
147

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss W. M. On the local reactions of the arterial wall to changes of internal pressure. J Physiol. 1902 May 28;28(3):220–231. doi: 10.1113/jphysiol.1902.sp000911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bloom S. R., Daniel P. M., Johnston D. I., Ogawa O., Pratt O. E. Release of glucagon, induced by stress. Q J Exp Physiol Cogn Med Sci. 1973 Jan;58(1):99–108. doi: 10.1113/expphysiol.1973.sp002195. [DOI] [PubMed] [Google Scholar]
  3. Bloom S. R. Progress report. Radioimmunoassay of intestinal hormones. Gut. 1974 Jun;15(6):502–510. doi: 10.1136/gut.15.6.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boden G., Chey W. Y. Preparation and specificity of antiserum to synthetic secretin and its use in a radioimmunoassay (RIA). Endocrinology. 1973 Jun;92(6):1617–1624. doi: 10.1210/endo-92-6-1617. [DOI] [PubMed] [Google Scholar]
  5. Dudl R. J., Lerner R. L., Ensinck J. W., Williams R. H. The effect of secretin on pancreatic glucoregulatory hormones in man. Horm Metab Res. 1973 Jul;5(4):250–253. doi: 10.1055/s-0028-1093940. [DOI] [PubMed] [Google Scholar]
  6. Fara J. W. Effects of gastrointestinal hormones on vascular smooth muscle. Am J Dig Dis. 1975 Apr;20(4):346–353. doi: 10.1007/BF01237791. [DOI] [PubMed] [Google Scholar]
  7. Fara J. W., Rubinstein E. H., Sonnenschein R. R. Intestinal hormones in mesenteric vasodilation after intraduodenal agents. Am J Physiol. 1972 Nov;223(5):1058–1067. doi: 10.1152/ajplegacy.1972.223.5.1058. [DOI] [PubMed] [Google Scholar]
  8. Fronek K., Stahlgren L. H. Systemic and regional hemodynamic changes during food intake and digestion in nonanesthetized dogs. Circ Res. 1968 Dec;23(6):687–692. doi: 10.1161/01.res.23.6.687. [DOI] [PubMed] [Google Scholar]
  9. Harvey R. F., Dowsett L., Hartog M., Read A. E. A radioimmunoassay for cholecystokinin-pancreozymin. Lancet. 1973 Oct 13;2(7833):826–828. doi: 10.1016/s0140-6736(73)90863-5. [DOI] [PubMed] [Google Scholar]
  10. Harvey R. F., Dowsett L., Hartog M., Read A. E. Radioimmunoassay of cholecystokinin-pancreozymin. Gut. 1974 Sep;15(9):690–699. doi: 10.1136/gut.15.9.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Henry R. W., Flanagan R. W., Buchanan K. D. Secretin: A new role for an old hormone. Lancet. 1975 Aug 2;2(7927):202–203. doi: 10.1016/s0140-6736(75)90672-8. [DOI] [PubMed] [Google Scholar]
  12. Reeder D. D., Becker H. D., Smith N. J., Rayford P. L., Thompson J. C. Measurement of endogenous release of cholecystokinin by radioimmunoassay. Ann Surg. 1973 Sep;178(3):304–310. doi: 10.1097/00000658-197309000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rehfeld J. F., Heding L. G. Increased release of gut glucagon in reactive hypoglycaemia. Br Med J. 1970 Jun 20;2(5711):706–707. doi: 10.1136/bmj.2.5711.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Richardson P. D. The actions of natural secretin on the small intestinal vasculature of the anaesthetized cat. Br J Pharmacol. 1976 Sep;58(1):127–135. doi: 10.1111/j.1476-5381.1976.tb07701.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Richardson P. D., Withrington P. G. The inhibition by glucagon of the vasoconstrictor actions of noradrenaline, angiotensin and vasopressin on the hepatic arterial vascular bed of the dog. Br J Pharmacol. 1976 May;57(1):93–102. doi: 10.1111/j.1476-5381.1976.tb07659.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Richardson P. D., Withrington P. G. The vasodilator actions of isoprenaline, histamine, prostaglandin E2, glucagon and secretin on the hepatic arterial vascular bed of the dog. Br J Pharmacol. 1976 Aug;57(4):581–588. doi: 10.1111/j.1476-5381.1976.tb10388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ross G. Cardiovascular effects of secretin. Am J Physiol. 1970 Apr;218(4):1166–1170. doi: 10.1152/ajplegacy.1970.218.4.1166. [DOI] [PubMed] [Google Scholar]
  18. Santeusanio F., Faloona G. R., Unger R. H. Inhibition of alanine-stimulated glucagon secretion by secretin in the dog. Horm Metab Res. 1973 Nov;5(6):425–427. doi: 10.1055/s-0028-1093916. [DOI] [PubMed] [Google Scholar]
  19. Temperley J. M., Stagg B. H., Wyllie J. H. Disappearance of gastrin and pentagastrin in the portal circulation. Gut. 1971 May;12(5):372–376. doi: 10.1136/gut.12.5.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Thompson J. C., Reeder D. D., Davidson W. D., Charters A. C., Brückner W. L., Lemmi C. A., Miller J. H. Effect of hepatic transit of gastrin, pentagastrin, and histamine measured by gastric secretion and by assay of hepatic vein blood. Ann Surg. 1969 Sep;170(3):493–505. doi: 10.1097/00000658-196909010-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weir G. C., Turner R. C., Martin D. B. Glucagon radioimmunoassay using antiserum 30K: interference by plasma. Horm Metab Res. 1973 Jul;5(4):241–244. doi: 10.1055/s-0028-1093958. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES